Michael Leslie, MD, PhD
Dr. Michael Leslie
Board-Certified Dermatologist & Dermatopathologist
He completed a bachelor of science in biology with honors, and a bachelor of art in geography at the University of Missouri. After finishing college, Dr. Leslie went on to earn a PhD in biomedical science at the University of Texas M.D. Anderson Cancer Center in Houston. His doctoral research focused on the development of a genetic vaccine for the treatment of melanoma. He has numerous publications in medical journals and has presented at multiple conferences.
After completing his PhD, Dr. Leslie attended medical school at the University of Texas at Houston, where he graduated as a member of the Alpha Omega Alpha honor society. He completed his dermatology residency at the University of Texas at Houston where he was chief resident, and pursued a fellowship in dermatopathology at the University of Texas Medical Branch in Galveston.
Dr. Leslie was born and raised in Kansas City, Missouri and spent his childhood traveling the Midwest playing tennis. An avid sports fan, he closely followed the Kansas City Chiefs, Royals, and his beloved Missouri Tigers. His desire to attend the University of Missouri was fulfilled when he was accepted to "MIZZOU" as a Division I tennis player. While earning his two undergraduate degrees, Dr. Leslie made first team Academic All Big XII Conference each year.
Dr. Leslie became interested in medicine while completing an undergraduate research project on the transmission of meningitis. It was during this time that he met his wife, Shana, a fellow student. Upon graduating from the University of Missouri, they moved to Houston, Texas to further their education.
Dr. Leslie chose to delve deeper into the biomechanics of disease and enrolled at the University of Texas Graduate School of Biomedical Science. For the next several years, he worked on the development of a genetic vaccine for the treatment of melanoma at M.D. Anderson Cancer Center. With growing interests in the clinical presentation of disease, Dr. Leslie decided to pursue a medical degree after completing his PhD in biomedical science in 2005.
While attending the University of Texas Medical School at Houston, Dr. Leslie welcomed two daughters into the world. Four years and several diapers later, he went on to complete his internal medicine year and dermatology residency at the University of Texas Medical School at Houston, where he was chief resident.
Wanting to link his biomolecular knowledge with his medical expertise, Dr. Leslie completed a dermatopathology fellowship at the University of Texas Medical Branch in Galveston, where he also served as a member of the faculty as a clinical instructor.
After spending many years in Texas, Dr. Leslie and his wife wanted to find an area where they could be close to family and raise their children. They moved to Colorado Springs in 2014 and joined Vanguard Skin Specialists. They have been honored to be part of a practice whose principles of excellence strive to make a positive impact on patients, the community, and the world at large.
Dr. Leslie has enjoyed exploring the many wonders of Colorado, often based upon his patients' personal recommendations. Although he has yet to take up rattlesnake hunting, he has enjoyed touring local breweries, hiking the many peaks, and uncovering some of the state's hidden gems.
In his spare time, Dr. Leslie enjoys brewing beer, playing guitar, and cooking authentic Kansas City bar-b-que while cheering on his Missouri Tigers.
- Leslie MC and Bar-Eli M. Regulation of Gene Expression in Melanoma: New Approaches for Treatment. Journal of Cellular Biochemistry, 2005 Jan 1;94(1):25-38.
- Leslie MC, Zhao YJ, Lachman LB, Hwu P, Wu GJ, Bar-Eli M. Immunization Against MUC18/MCAM, a Novel Antigen Which Drives Melanoma Invasion and Metastasis. Gene Therapy, 2007 Feb;14(4):316-23.
- Shields JM, Thomas NE, Cregger M, Berger AJ, Leslie M, Torrice C, Hao H, Penland S, Arbiser J, Scott G, Zhou T, Bar-Eli M, Bear JE, Der CJ, Kaufmann WK, Rimm DL, Sharpless NE. Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma. Cancer Research, 2007 Feb 15;67(4):1502-12.
- Schwartz B, Shoseyov O, Melnikova VO, McCarty M, Leslie M, Roiz L, Smirnoff P, Hu GF, Lev D, Bar-Eli M. ACTIBIND, a T2 RNase, competes with angiogenin and inhibits human melanoma growth, angiogenesis, and metastasis. Cancer Research, 2007 Jun 1;67(11):5258-66.
Villares GJ, Zigler M, Wang H, Melnikova VO, Wu H, Friedman R, Leslie MC, Vivas-Mejia P, Lopez-Berestein G, Sood AK and Bar-Eli M. Targeting Melanoma Growth and Metastasis with Systemic Delivery of Liposomal Incorporated PAR-1 siRNA. Cancer Research. 2008 Nov 1;68(21):9078-86.